Mode
Text Size
Log in / Sign up
Phase 4 Completed N=32 Randomized Double-blind Treatment

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

Primary Hypercholesterolemia
Source: ClinicalTrials.gov NCT00746811 ↗
Enrolled (actual)
32
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Percent Change From Baseline in LDL-C During Each Treatment — 3.4; -0.7 Percent change from baseline
◆ Published Evidence
Established
31citations · ~2 / year
Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
Journal of cardiovascular pharmacology · 2011 · High-confidence link

Summary

The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo, on LDL-C and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.

Linked Publications

  • Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Journal of cardiovascular pharmacology · 2011 · 31 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in LDL-C During Each Treatment
3.4; -0.7
SECONDARY
Percent Changes in Other Lipid and Biomarker Levels
0.5; -0.7; -16.7; 2.0; 1.5; -1.7

Eligibility Criteria

Inclusion Criteria

  • Men and women, ages 18-79 inclusive
  • Fasting, untreated low-density lipoprotein cholesterol (LDL-C)level in the borderline high to very high range
  • Fasting, untreated triglyceride (TG)level in the normal range
  • Provide written informed consent and authorization for protected health information

Exclusion Criteria

  • CHD or CHD risk equivalent
  • Pregnancy
  • Use of lipid altering medications which cannot be stopped
  • Body mass index over 45 kg per square meter
  • Allergy or sensitivity to omega-3 fatty acids
  • Certain muscle, liver, kidney, lung or gastrointestinal conditions
  • Poorly controlled hypertension
  • Certain medications
  • Active cancers treated within prior 2 years (except non-melanoma skin cancer)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00746811) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search